started · updated
Brazilian pharmaceutical sector warns of medicine shortages
Six major representative entities of the Brazilian pharmaceutical sector have issued a joint warning to the National Congress regarding a concrete risk of medicine shortages across the country starting in 2027. The group, which includes manufacturers, distributors, and pharmacy chains, is requesting a postponement of at least one year for key milestones in the implementation of the tax reform on consumption.
The primary concern involves the introduction of the Contribution on Goods and Services (CBS), a federal value-added tax intended to replace PIS and Cofins. Industry leaders argue that the federal government's delay in publishing complementary regulations, specifically the definition of the reference CBS rate, prevents companies from updating necessary accounting and logistical systems.
Representatives state that failures in issuing fiscal documents or the lack of adequate price lists could paralyze billing and product circulation. The sector emphasizes that the transition is uniquely complex due to price controls by the Drug Market Regulation Chamber (CMED), slim profit margins, and the logistical demands of over 90,000 pharmacies nationwide. The group maintains that these regulatory uncertainties pose a direct threat to public health policy.
Entities
Abrafarma · Brazil · Brazilian Congress · Drug Market Regulation Chamber · Sindusfarma